quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:07:57·38d
INSIDERFiling
Castle Biosciences Inc. logo

Chief Commercial Officer Juvenal Tobin W sold $526,582 worth of shares (20,863 units at $25.24), decreasing direct ownership by 19% to 86,825 units (SEC Form 4)

CSTL· Castle Biosciences Inc.
Health Care
Original source

Companies

  • CSTL
    Castle Biosciences Inc.
    Health Care

Recent analyst ratings

  • Dec 14UpdateGuggenheim$25.00
  • Jan 5UpdateScotiabank$54.00
  • Jan 7UpdateStephens & Co.$59.00
  • Nov 9UpdateSVB Leerink$75.00
  • Jul 14UpdateSVB Leerink$85.00

Related

  • INSIDER19h
    Pres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $104,709 worth of shares (4,172 units at $25.10) as part of a pre-agreed trading plan (SEC Form 4)
  • PR3d
    Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
  • PR9d
    Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
  • PR14d
    Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
  • INSIDER15d
    SEC Form 4 filed by Maetzold Derek J
  • SEC16d
    SEC Form DEFA14A filed by Castle Biosciences Inc.
  • SEC16d
    SEC Form DEF 14A filed by Castle Biosciences Inc.
  • INSIDER24d
    SEC Form 4 filed by Maetzold Derek J
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022